Transcriptional profiling of peripheral blood in pancreatic cancer patients revealed that ANKRD22 mRNA was upregulated and could serve as a diagnostic biomarker in patients with AUC = 0.933 (39). This evidence concerns the gene ANKRD22 and familial pancreatic carcinoma.